Colorado company wins FDA approval for COVID-19 clinical study


ENGLEWOOD, Colo. (KDVR) — An anti-inflammatory drug will soon be tested on COVID-19 patients at Penrose Hospital in Colorado Springs. Englewood-based Ampio Pharmaceuticals has won FDA approval to do a clinical study using its drug Ampion.

“I am ecstatic,” Dr. David Bar-Or, founder of Ampio Pharmaceuticals, said. 

The clinical trial will begin small, with just 10 patients, in July. Five patients will receive Ampion and five will not.

“Hopefully it prevents a patient who needs oxygen from having to be put on a ventilator,” said Bar-Or, who said Ampion works by reducing inflammation in the lungs so patients can breathe better.

Bar-Or said patients who end up on a ventilator still die 40-50 percent of the time, so Ampion will be given both to patients on a ventilator and to patients before they need a ventilator.

Patients will be given two doses a day for five days.

“What I expect to see is something very rapidly — something happen very rapidly. Improvement in oxygenation parameters and perhaps the well-being of the patient,” said Bar-Or before adding, “When we do in-vitro studies in cell cultures, we see the results within 24 hours.” 

If patients’ results show promise, the study will be expanded to four other hospitals.

Most Read

Top Stories

More Home Page Top Stories